Smither John W
SEC insider (Form 3/4/5 filer). CIK 0001559583. Director at NewAmsterdam Pharma Co N.V. (NAMS) and 3 other issuers. 9 reported Form 4/5 transactions since Sep 2024; latest on Sep 4, 2026. Located in NAARDEN.
Companies Smither John W has filed insider reports for
- NewAmsterdam Pharma Co N.V. (NAMS): Director
- Attovia Therapeutics, Inc. (ATTO): Director
- MBX Biosciences, Inc. (MBX): Officer, Chief Financial Officer
- GENELUX Corp (GNLX): Director
Smither John W
CIK: 0001559583
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 4, 2026NAMS
NewAmsterdam Pharma Co N.V.
SaleDirect1.6K shares at avg. $25.32$41K - Aug 3, 2026MBX
MBX Biosciences, Inc.
AwardDirect28K shares- - Jul 1, 2026GNLX
GENELUX Corp
SaleDirect12K shares at avg. $2.91$35K - Jun 16, 2026GNLX
GENELUX Corp
AwardDirect28.4K shares- - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
AwardDirect3.4K shares- - Aug 27, 2025GNLX
GENELUX Corp
AwardDirect22.3K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirect7K shares- - Jan 6, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirectOption (right to buy)
32.5K shares- - Aug 1, 2024GNLX
GENELUX Corp
AwardDirectStock Option Right to Buy)
50.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 |  NAMS NewAmsterdam Pharma Co N.V. | Sale | 1,600 | $25.32 | $40,512 | Direct |
| Aug 3, 2026 |  MBX MBX Biosciences, Inc. | Award | 28,000 | - | $0 | Direct |
| Jul 1, 2026 |  GNLX GENELUX Corp | Sale | 12,000 | $2.91 | $34,898 | Direct |
| Jun 16, 2026 | GNLX GENELUX Corp | Award | 28,409 | - | $0 | Direct |
| Jan 7, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Award | 3,400 | - | $0 | Direct |
| Aug 27, 2025 | GNLX GENELUX Corp | Award | 22,283 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award | 6,960 | - | $0 | Direct |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award Option (right to buy) | 32,500 | - | - | Direct |
| Aug 1, 2024 | GNLX GENELUX Corp | Award Stock Option Right to Buy) | 50,469 | - | - | Direct |
1-9 of 9 transactions